Please assess the completion status of the following clinical trial:

Trial Title: Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* \>=2 International Statistical Classification of Diseases and Related Health Problems (ICD)-10-CM diagnosis codes for COPD at least 30 days apart during the 12 month period prior to sample identification.~* Diagnosis codes J40-J44 will be included.~* \>=1 pharmacy claim for UMEC/VI or FLUT/SAL single-inhaler dual therapy during Baseline.~* Age \>= 65 years.~* Self-reported health care provider diagnosis of COPD.~* Self-reported prescription for FLUT/SAL or UMEC/VI.~* 12 months of continuous enrollment during the Baseline period.~* Ability to complete the study survey in English.~Exclusion Criteria:~* \>=2 ICD-10-CM diagnosis codes for asthma at least 30 days apart during the, 12 month period, prior to sample identification.~* Claims for both UMEC/VI and FLUT/SAL in the 6 months, closest to sample identification.~* Claims for triple therapy (Inhaled Corticosteroid \[ICS\] + Long-acting Antimuscarinic \[LAMA\] + Long-acting Beta-agonist \[LABA\] during the Baseline period.~* Evidence of lung cancer diagnosis and/or treatment

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- UMEC/VI (Type: None): The subjects in this arm had received, UMEC/VI as 62.5/25 microgram (mcg), which is an approved once-daily single inhaler dual LAMA/LABA therapy, given via Ellipta .
- FLUT/SAL (Type: None): The subjects in this arm had received, FLUT/SAL as 250/50 mcg, which is an approved twice-daily single inhaler dual therapy ICS/LABA treatment, given via DISKUS.

Based on this trial design, predict the completion outcome and termination type (if applicable).